How Tariffs on Pharmaceuticals Are Reshaping Global Drug Prices

At a Glance

• Since September 29, 2026, imported patented drugs and their ingredients face a 100% U.S. duty unless a lower rate applies.
• Products of the EU, Japan, South Korea, Switzerland and Liechtenstein face a 15% total rate instead.
• Generic drugs and their ingredients carry no extra Section 232 duty for now.
• A July 2026 social media post outlined future generic duties, but the legal exemption still stands.
• Company onshoring plans and pricing agreements can lower a company’s rate to 20% or zero.
• Price effects depend on pass-through, exemptions and rebates, so plan by product, origin and supplier.

What You’ll Learn

This guide explains the 2026 U.S. tariff rates, which drugs and ingredients they cover, how prices and supply chains may react, and how importers can respond.

Introduction

Tariffs on pharmaceuticals moved from threat to law in 2026. A Section 232 proclamation set a 100% duty on many imported patented drugs and their active ingredients. The final phase began on September 29, 2026. Rates vary by product, origin and company, so the headline number rarely tells the whole story for any single product.

This guide is for procurement teams, importers and analysts who need the current rules, not the 2025 proposals. It explains who pays which rate, what is exempt, and how prices and supply chains may respond. It also covers practical ways to reduce exposure and the dates that matter for planning.

For a consumer view of drug costs and U.S. manufacturing, read our guide to U.S. pharmaceutical tariffs.

The Current Tariff Landscape in Pharmaceuticals

The 2026 rules replace the proposals that shaped most 2025 coverage. A presidential proclamation issued on April 2, 2026 now sets rates for patented drugs and their active pharmaceutical ingredients (APIs). It uses Section 232 of the Trade Expansion Act. Rates differ by product, origin and company.

How Section 232 Pharmaceutical Tariffs Work

The presidential proclamation frames the action as national security policy. It says about 53 percent of patented pharmaceutical products distributed in the United States are produced abroad. It adds that only 15 percent of patented APIs by volume are made domestically. Duties began phasing in on July 31, 2026, and the final phase took effect on September 29, 2026.

The table shows which rate applies in each situation. Rates apply to products listed in the proclamation’s annexes, so confirm each tariff heading with a customs broker.

Your situation	Rate	What to check
Patented drug or API, no special status	100%	Annex I tariff heading and importer of record
Product of the EU, Japan, South Korea, Switzerland or Liechtenstein	15% total	Country of origin documents
Company with an approved onshoring plan	20%, rising to 100% on April 2, 2030	Plan approval from Commerce
Company with an onshoring plan and a most-favored-nation pricing agreement	Zero until January 20, 2029	Agreement with HHS
Listed specialty product	Zero, if conditions are met	Product category and eligible jurisdiction
Generic drug or ingredient	Zero	Customs definition of a generic article
Clinical trial, R&D or noncommercial use only	Zero	Documents showing sole use

Specialty products include orphan-only drugs, nuclear medicines, plasma-derived therapies and fertility drugs. They also include cell and gene therapies, antibody-drug conjugates and animal health products. They qualify for the zero rate in two cases. The product comes from a jurisdiction with a trade and security framework, or Commerce finds an urgent U.S. health need.

Earlier coverage cited a 250% ceiling. That figure came from public remarks in 2025. The proclamation sets a 100% base rate, and the tariffs on pharmaceuticals now in force follow the table above.

Product Category	Country/Region	Current Tariff Rate	Target Impact
Active Pharmaceutical Ingredients	China	Up to 245%	Force domestic production
Medical Devices	Canada/Mexico	25%	Reduce NAFTA dependencies
Finished Pharmaceuticals	All Countries	10% baseline	General import reduction
Manufacturing Equipment	Switzerland/Germany/India	25%	Increase domestic facility costs

Immediate Market Impact and Price Projections

The 100% phase began on September 29, 2026, so firm evidence of price effects is still thin. The best-known estimate predates the final rules. An EY analysis for the industry group PhRMA modeled a flat 25% tariff on all pharmaceutical imports. Reuters reported it in April 2025.

That analysis found a cost of nearly $51 billion a year. It projected prices up to 12.9% higher if duties were fully passed on. The report says it is unclear how much would reach consumers. Distributors that pay the duty may absorb part of it.

Treat these figures as a scenario, not a forecast of current pharma tariffs. The 2026 rules are tiered, and many products pay less than 100% or nothing. Legal analysts at WilmerHale say the duties may substantially increase import costs. They also note that supply chain changes can affect Medicaid Drug Rebate Program calculations and 340B ceiling prices.

Global Supply Chain Dependencies Under Pressure

A duty on a finished drug is only part of the exposure. The proclamation covers APIs and key starting materials alongside patented finished products. A pharmaceutical supply chain also crosses several borders before a drug reaches a pharmacy. One tariff can touch more than one stage.

Asia-Pacific Manufacturing Dominance

India’s own figures show how tightly the chain is linked. Madhyamam reported in March 2026 on a written reply in India’s upper house. It said India still imports more than 70 percent of several critical drug ingredients from China. The reply put intermediates for rifampicin and methyldopa at 100 percent dependence.

• Penicillin raw material: dependence on China for 6-APA was nearly 96 percent in FY2025.
• Antibiotic ingredients: erythromycin, gentamicin, streptomycin, tetracycline and norfloxacin were reported above 90 percent.
• Finished goods: a drug made in India can still rely on Chinese intermediates.

This structure means a tariff on one country can affect several supply chains. A buyer who switches the finished-dose supplier does not remove upstream exposure. Ask each supplier where its intermediates come from before you assume the origin has changed.

European Union’s Strategic Position

The United States imported $213 billion of pharmaceuticals in 2025, according to the BTS import summary, which uses Census data. Ireland (42.4billion),Germany(26.1 billion) and Switzerland ($19 billion) were the three largest sources. These pharmaceutical imports now meet different tariff rates depending on origin.

Products of the EU, Switzerland and Liechtenstein face a 15% total rate instead of 100%. The proclamation says these rates implement existing trade-deal commitments. That gives manufacturers in Ireland, Germany and Switzerland a cost edge over origins that pay the default rate. The 15% rate still applies, though.

Raw Material and API Vulnerabilities

The proclamation treats APIs of patented drugs like the finished product, at the same Annex I rate. It does not set a higher rate for ingredients. Generic APIs currently carry no extra duty, so exposure depends on whether the end drug is patented.

New ingredient sources need quality checks and regulatory approval before they can ship, which takes time. Analysts cited by AJMC warn that low-margin generics, especially sterile injectables, face shortage risk if future duties push suppliers out. That risk is a forecast, not an observed result.

Planning sourcing under changing import duties? Request a Quote

Regional Market Responses to Pharmaceutical Tariffs

Governments and companies respond to the same rule in different ways. The proclamation rewards companies that commit to U.S. production and pricing terms. It applies the default 100% rate to those that do not.

United States: Reshoring Manufacturing Initiatives

The proclamation ties lower rates to onshoring. Companies with an approved plan pay 20%, which rises to 100% on April 2, 2030. Companies that also hold a most-favored-nation pricing agreement with HHS pay zero until January 20, 2029.

The Bureau of Industry and Security asked for onshoring applications by June 12, 2026. WilmerHale notes that late applicants may still qualify. New plants take years to build, so agreements deliver tariff relief faster than new capacity does.

India and China: Where Exposure Sits

India is the largest foreign supplier of generics to the United States, according to AJMC reporting. Generics currently carry no extra Section 232 duty, so finished generic exports from India do not pay that duty today.

The risk sits upstream and in the future. Indian makers depend on China for many intermediates, as the figures above show. Our guide to chemical sourcing from India covers India’s role for buyers.

A duty on generics would raise the stakes. Our review of India’s chemical sector tariffs covers wider trade effects.

Alternative Sourcing Jurisdictions and the Zero Rate

Commerce’s September 23, 2026 notice lists jurisdictions whose specialty products can qualify for the zero rate. They have, or expect, a trade and security framework agreement with the United States. The list covers these places:

• Americas: Argentina, Ecuador, El Salvador and Guatemala.
• Europe: the European Union, North Macedonia, Switzerland and Liechtenstein, and the United Kingdom.
• Asia and the Middle East: Bangladesh, Cambodia, India, Indonesia, Japan, Jordan, Malaysia, South Korea, Taiwan, Thailand and Vietnam.

The zero rate applies to specialty categories only, not to all drugs from these places. Commerce says the list may change in a future notice.

Industry-Wide Cost Implications

The effects of tariffs on the pharmaceutical industry reach payers, hospitals and patients as well as manufacturers. Who pays depends on whether a product is patented, which company imports it and how rebates are set. Early evidence is limited because the final phase began recently.

Generic vs. Branded Drug Price Pressures

Branded and patented drugs face the Section 232 duty today. Generics do not. The gap explains why tariffs on generic drugs draw so much attention, even though none are in force.

On July 21, 2026, President Trump posted a plan for generics. It sets zero for two years from August 1, 2026, then 100% for one year, then 200%. AJMC and Fox Business reported the post. It is not a legal instrument. Commerce’s September 23, 2026 notice still states that generics are not subject to the tariffs. Treat the plan as a risk, not a schedule.

Analysts warn that thin margins could push some generic makers out of low-margin products if buyers cannot absorb higher costs. That warning concerns future duties. Branded makers have more room to negotiate, because onshoring and pricing agreements lower their rate.

The proclamation also excludes biosimilars at this time. WilmerHale advises importers not to rely on labels such as “biosimilar” or “authorized generic”. Confirm the customs definition instead.

Healthcare System Burden Analysis

Tariff effects reach healthcare budgets through several channels. Some are direct, such as import costs. Others work through government pricing programs. Early data is thin, so read the points below as pressure points to monitor.

• Government programs: supply chain changes can alter Medicaid Drug Rebate Program calculations and 340B ceiling prices.
• Payers and patients: how much of any duty reaches premiums or out-of-pocket costs is not yet measurable.
• Distributors and retailers: those that pay the duty may absorb part of it, as the EY report notes.
• Clinical research: articles imported only for clinical trials, R&D or noncommercial use carry zero additional duty.

Strategic Adaptations by Pharmaceutical Companies

Companies have three levers. They can change where they make a drug, who supplies it, or the contract terms that set their rate. Each lever has a cost and a timeline. The right mix depends on product type and volume.

Domestic Manufacturing Investments

Companies weigh the cost of new U.S. capacity against the duty they would otherwise pay. An approved onshoring plan holds the rate at 20% only until April 2, 2030. The plan must deliver real capacity by then. The proclamation lets Commerce raise rates if commitments are missed. It also allows tariffs to be reimposed retroactively if a company misleads officials about onshoring.

Regulatory approval and validation take time before a new site can ship. Workforce training adds more. Domestic capacity therefore helps in the medium term, not this quarter.

Supply Chain Diversification Strategies

Companies develop multi-sourcing strategies across different geographic regions. Supplier qualification processes accelerate to establish alternative sources quickly. Risk management frameworks incorporate tariff scenarios into procurement decisions. Our guide to material sourcing strategy compares the main approaches.

Long-term contracts provide price stability while locking in supplier relationships. Strategic partnerships with regional manufacturers create backup production capacity. Qualify any new source against your own checklist first. Our supplier approval checklist lists the documents to request.

Tariff Mitigation in Pharma: Duty Planning Options

The first step is getting classification and origin right, because each rate attaches to a tariff heading. WilmerHale’s analysis lists several options once the facts are clear. Not every option fits every importer.

1. Confirm classification: do not rely on commercial labels. Check whether the product is patented or generic under the customs definition.
2. Claim drawback: duties paid can be recovered when goods are exported or destroyed, if tracing and documents support the claim.
3. Use a foreign trade zone: admission can defer duties. The proclamation limits the benefit for goods that enter U.S. commerce.
4. Seek an onshoring agreement: it commits you to U.S. capacity in exchange for a lower rate.
5. Request urgent-need treatment: for a specialty product, Commerce decides each request company by company.

Technology and Automation Solutions

Better data helps most when rules change quickly. Digital supply chain tools can track origin, classification and duty status by lot, which supports both compliance and drawback claims. Advanced manufacturing can lower unit costs at U.S. sites, but it does not change the tariff rate.

Long-term Market Transformation

How tariffs on pharmaceuticals shape the industry over several years depends on a few dated decisions. The proclamation sets milestones, and the generics plan adds a second track. The table lists the dates that matter most for planning.

Date	What happens	Source
Within one year of April 2, 2026	Commerce reports on whether generics need action	Proclamation
January 20, 2029	Zero rate ends for companies with onshoring and pricing agreements	Proclamation
April 2, 2030	The 20% onshoring rate rises to 100%	Proclamation
2028 and 2029 (announced)	Generic duties of 100%, then 200%, if the July 2026 plan becomes law	Social media post, reported by AJMC

Reshaping Global Trade Patterns

Different rates by origin change the math on where to source. Products from the EU, Japan, Korea and Switzerland pay 15%, against 100% by default. That gives buyers a reason to review origin. Trade flows may shift toward lower-rate origins, but contracts, approvals and capacity limit how fast. Any shift is a projection, not a measured result.

Innovation and R&D Impact

Research supplies are partly protected. Articles imported solely for clinical trials, R&D or noncommercial use carry no additional duty. Commercial launch supply is treated differently, so teams should separate trial and commercial shipments in their records. The longer-term effect on investment is uncertain.

Reshore, Diversify or Absorb: Which Response Fits?

No single response works for every importer. The right choice depends on three things. They are whether your products are patented, how much volume you move and how long the exposure lasts. Match your situation to a response before you commit capital.

Choose this response	If	Watch for
Onshoring agreement	You sell patented products in the U.S. at scale and can fund capacity	The 2030 step to 100% and Commerce’s right to raise rates if commitments are missed
Supplier diversification	Your ingredients are commodity inputs with several qualified sources	Hidden upstream dependence on one country
Duty recovery or deferral	You re-export, destroy or hold goods before sale	Tracing, documents and trade zone limits
Absorb or reprice	Volumes are small or the exposure looks temporary	Margin limits and rebate effects

Sourcing teams for chemical inputs can start by comparing qualified suppliers across origins. Not sure which route fits your inputs? Request a Quote

FAQs

These answers cover points the sections above leave open. Rules can change, so confirm current status with trade counsel before you act.

1. Which drugs are affected by the tariffs?

Patented pharmaceuticals and their associated ingredients listed in Annex I of the proclamation are covered. Generic drugs and ingredients, listed specialty products and clinical trial supplies carry a zero additional rate. Rates differ by company and origin. Check the tariff heading for each product with a customs broker before you ship.

2. Is a 250% pharmaceutical tariff in effect?

No. The 250% figure came from remarks made in 2025. The April 2026 proclamation sets a 100% base rate for patented drugs and ingredients. Some origins and companies pay less. A separate July 2026 plan for generics mentions 200% from 2029, but it has no legal text.

3. Do the tariffs apply to drugs made in the United States?

No. The proclamation says U.S.-origin pharmaceutical products are not subject to the tariffs. A U.S. plant can still import ingredients. Those may carry duty if they are APIs for patented products listed in Annex I. Review your bill of materials by origin and tariff heading.

4. Will prescription drug prices rise because of the tariffs?

It depends on the product. Many patented drugs pay less than 100%, generics pay nothing for now, and distributors may absorb part of any duty. Firm evidence is limited because the final phase began on September 29, 2026. Watch rebates and company pricing agreements, which can offset or shift costs.

5. Where can I check whether a product is covered?

Start with the tariff headings in the proclamation’s annexes and the Commerce notice of September 23, 2026. For a specialty product that may meet an urgent U.S. health need, Commerce accepts one application per product. A customs broker or trade counsel can confirm classification.

6. What is Section 232?

Section 232 of the Trade Expansion Act of 1962 lets the president adjust imports for national security reasons. The pharmaceutical proclamation cites heavy foreign production of patented drugs and ingredients. It is a different authority from other U.S. tariff programs, so confirm which program applies to each product.

Conclusion

Tariffs on pharmaceuticals in 2026 depend on three facts. They are whether the drug is patented, where it is made, and which agreements the importer holds. Generics are exempt for now, but the July 2026 plan makes them a risk to monitor.

Plan by product, origin and supplier, and track the dates in this guide. Keep records that let you claim relief when it applies. Elchemy helps companies optimize supply chain strategies as trade rules change.

Request a Quote to compare qualified sources for your inputs.